
According to data from Benzinga Pro, during Q1, Intercept Pharmaceuticals's (NASDAQ:ICPT) reported sales totaled $88.58 million. Despite a 52.36% increase in earnings, the company posted a loss of $17.28 million. Intercept Pharmaceuticals collected $92.40 million in revenue during Q4, but reported earnings showed a $36.28 million loss.